Compare Abeona Therapeutics Inc (ABEO) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Rockwell Automation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Rockwell Automation trades at $462.66 (market cap $52.18B). The key difference: Rockwell Automation is far larger — about 139.8× Abeona Therapeutics Inc's market cap, and Rockwell Automation pays a 1.18% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ROK | |
|---|---|---|
Market Cap | $373.32M | $52.18B |
Sector | Health | Industrials |
52-Week High | $7.23 | $495.08 |
52-Week Low | $4.17 | $328.67 |
Enterprise Value | $228.22M | $55.81B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Rockwell Automation (ROK) trades at $468.9, down 0.59% today but near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Revenue remains stable at $8.34B (2025), though net margins have softened to 10.41%. Recent news highlights AI infrastructure opportunities and product launches like FactoryTalk Orchestration, positioning ROK for industrial digital transformation growth.
Outlook remains positive with analyst consensus leaning toward Hold/Buy, targeting $463.86. Key opportunities include AI-driven industrial automation demand, while risks involve margin pressure and cyclical industry exposure. Valuation multiples (P/E 50.14) suggest premium pricing, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
